



Press release

Stockholm, April 29, 2009

Interim Report – January to March 2009

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and albumin binding technology, today issued its Interim Report covering the First Quarter 2009.

Financial Highlights

- Revenue for the 1st Quarter 2009 was SEK 5.7 (4.9) million
- Net loss for the period amounted to SEK –11.9 (-26.9) million
- Earnings per share was SEK –0.40 (-0.90)
- Cash flow from current operations was SEK –13.8 (-15.0) million

Key Corporate Highlights

- A collaboration agreement has been signed with Biovitrum AB with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases. This is in line with Affibody’s new strategy, aiming to generate profitable corporate partnerships across the life science sector based on its unique proprietary technology platforms: Affibody® molecules and albumin binding technology and designed to allow Affibody to reach its key corporate objective of sustainable profitability in the next two years.
- During the period, Affibody obtained the third and final approval required to commence a Phase I study in Germany with its lead molecular imaging agent, ABY-025, which is based on a highly specific Affibody® molecule that binds the breast cancer marker HER2.
- Affibody’s proprietary albumin binding technology has gained interest from several companies searching for a relevant drug development technology.

David Bejker CEO, said: *“The collaboration with Biovitrum represents an important step in Affibody’s efforts to become profitable within the coming two years and is the first collaboration with our novel biopharmaceutical concept, based on the Second Generation Affibody® molecules and the Second Generation of our albumin binding technology. We believe that Biovitrum is an ideal partner for the development and commercialization of products based on our technology platforms. Given the power of these two technology platforms and our increased business development activities I look forward to announcing more collaborations over the coming months.”*

Enquiries

David Bejker, CEO
Johan Stuart CFO

+46 706 454 948
+46 706 644 096

About Affibody

Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and albumin binding technology.

Affibody® molecules, which are small, robust and easily produced, can be designed to bind specifically to a large number of target proteins. They have a broad range of applications including protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostics, including molecular imaging, and targeted therapeutics.

Affibody is also commercializing its unique albumin binding technology designed to enhance the efficacy of biotherapeutics by extending their circulation time.

Affibody has already developed biotechnological products that are commercialized by GE, Agilent and Finnzymes, and is developing Affibody® molecules for further biotechnology applications in a number of commercial collaborations.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include the investment companies HealthCap, Investor Growth Capital and SV Life Sciences.

Further information can be found at: www.affibody.com

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Affibody's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, future capital needs and the uncertainty of additional funding, as well as various legal hazards.